Degenerative Disc Disease Market to Observe Stupendous Growth at ~19% CAGR by 2036, Due to Launch of Novel Drug Classes Such as Cell Replacement, NF-kappa B Inhibitors, Cartilage Regeneration via TGF-β1 Expression, and Others | DelveInsight
The degenerative disc disease market is witnessing a paradigm shift, transitioning from traditional symptom-focused treatments and surgical procedures toward regenerative and disease-modifying therapies. Emerging pipeline candidates, including SB-01 (Spine Biopharma), IDCT (DiscGenics), Rexlemestrocel-L (Mesoblast and Grünenthal), AMG0103 (AnGes), BRTX-100 (BioRestorative Therapies), and others, are reshaping the DDD market landscape.
LAS VEGAS, July 20, 2026 /PRNewswire/ -- Recently published Degenerative Disc Disease Market Insights report includes a comprehensive understanding of current treatment practices, degenerative disc disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Degenerative Disc Disease Market Summary
Discover what is the future of the degenerative disc disease treatment market @ https://www.delveinsight.com/report-store/degenerative-disc-disease-ddd-market
Key Factors Driving the Growth of the Degenerative Disc Disease Market
According to Sharad Chandra Vinayak, Assistant Project Manager of forecasting at DelveInsight, growing research in regenerative medicine, including stem cell therapy, biologics, and tissue-engineered disc replacement technologies, presents significant opportunities for disease-modifying treatments in DDD.
Degenerative Disc Disease Market Analysis
Degenerative Disc Disease Competitive Landscape
Some of the degenerative disc disease drugs under development include SB-01 (Spine Biopharma), IDCT (Rebonuputemcel) (DiscGenics), Rexlemestrocel-L (MPC-06-ID) (Mesoblast and Grünenthal), AMG0103 (NF-κB decoy oligonucleotide) (AnGes), BRTX-100 (BioRestorative Therapies), TG-C (Kolon TissueGene), Allogenic BM-MSCs (Citospin), CELZ-201-DDT (Creative Medical Technology), and others.
Spine Biopharma's SB-01 (Vicatertide) is a first-in-class investigational therapy being developed for the treatment of degenerative disc disease, intending to alleviate pain, improve functional outcomes, and slow disease progression. Delivered through a minimally invasive intradiscal injection, SB-01 is a synthetic seven-amino acid peptide that selectively targets Transforming Growth Factor Beta 1 (TGFβ1), a signaling protein commonly overexpressed in degenerated intervertebral discs. By suppressing excessive TGFβ1 activity, the therapy is intended to preserve disc structure, reduce disc-related pain, and address the underlying pathology of chronic low back pain rather than merely providing symptomatic relief. In August 2025, Spine BioPharma reported positive topline results from the Phase III MODEL trial evaluating SB-01 (vicatertide) in patients with chronic low back pain associated with degenerative disc disease.
DiscGenics's IDCT is a novel, single-dose biologic therapy designed to both halt the progression of symptomatic lumbar disc degeneration and stimulate regeneration of damaged discs from within. The treatment involves a one-time, percutaneous injection directly into the affected intervertebral disc, eliminating the need for surgery. Recognizing its potential to address significant unmet medical needs, the therapy has received both Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the US FDA. IDCT is currently being assessed in an accelerated Phase III clinical development program, comprising two identical parallel studies approved by the FDA: the pivotal DGX-A02 (PIVOT) trial and the confirmatory DGX-A03 (CONFIRM) trial.
BioRestorative Therapies' BRTX-100 is an investigational autologous mesenchymal stem cell therapy intended for the treatment of chronic discogenic pain caused by degenerative disc disease. The therapy utilizes mesenchymal stem cells harvested from the patient's own bone marrow, which are expanded under controlled conditions before being injected into damaged spinal discs through a minimally invasive procedure. Designed as a potential alternative or complement to surgical intervention, BRTX-100 aims to repair disc tissue and reduce chronic pain. The therapy is currently undergoing Phase II clinical evaluation for chronic lumbar DDD-related pain and has also received US FDA Investigational New Drug (IND) clearance for the treatment of chronic cervical discogenic pain.
The anticipated launch of these emerging therapies are poised to transform the degenerative disc disease market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the degenerative disc disease market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about which pipeline drugs could transform degenerative disc disease treatment @ Degenerative Disc Disease Drugs
Recent Developments in the Degenerative Disc Disease Market
Degenerative Disc Disease Epidemiology Segmentation
The degenerative disc disease epidemiology section provides insights into the historical and current degenerative disc disease patient pool and forecasted trends for the leading markets. In 2025, the US had the highest number of diagnosed prevalent cases of DDD, with nearly 14.2 million cases. This figure is expected to rise by 2036.
The degenerative disc disease treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:
Degenerative Disc Disease Market Report Metrics
Details
Study Period
2022–2036
Coverage
7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Degenerative Disc Disease Market CAGR
~19%
Degenerative Disc Disease Market Size in 2025
USD 1.2 Billion
Key Degenerative Disc Disease Companies
Spine Biopharma, DiscGenics, Mesoblast, Grünenthal, AnGes, BioRestorative Therapies, Kolon TissueGene, Citospin, Creative Medical Technology, and others
Key Degenerative Disc Disease Therapies
SB-01, IDCT (Rebonuputemcel), Rexlemestrocel-L (MPC-06-ID), AMG0103 (NF-κB decoy oligonucleotide), BRTX-100, TG-C, Allogenic BM-MSCs, CELZ-201-DDT, and others
Scope of the Degenerative Disc Disease Market Report
Download the report to understand the top emerging therapies in degenerative disc disease @ Degenerative Disc Disease Clinical Trials
Table of Contents
1
Degenerative Disc Disease Market Key Insights
2
Degenerative Disc Disease Market Report Introduction
3
Executive Summary of DDD
4
Key Events
5
Epidemiology and Market Forecast Methodology
6
DDD Market Overview at a Glance
6.1
Emerging Landscape Analysis (by Molecule Type, Phase, and Route of Administration [RoA])
6.2
Market Share of DDD by Therapies (%) in the 7MM in 2025
6.3
Market Share of DDD by Therapies (%) in the 7MM in 2036
7
Disease Background and Overview
7.1
Introduction
7.2
Types of DDD
7.3
Stages of DDD
7.4
Etiology of DDD
7.5
Risk Factors
7.6
Symptoms
7.7
Pathophysiology of DDD
7.8
Diagnosis
8
Treatment
9
Treatment Guidelines
9.1
CLBP: Clinical Practice Guideline from the American College of Physicians
10
Epidemiology and Patient Population of DDD in the 7MM
10.1
Key Findings
10.2
Assumptions and Rationale
10.3
7MM
10.3.1
Diagnosed Prevalence Cases of CLBP in the 7MM
10.3.2
Diagnosed Prevalence Cases of Specific CLBP in the 7MM
10.3.3
Diagnosed Prevalence Cases of DDD in the 7MM
10.4
The United States
10.4.1
Diagnosed Prevalence Cases of DDD in the United States
10.4.2
Severity-specific Cases of DDD in the United States
10.4.3
Age-specific Cases of DDD in the United States
10.4.4
Type-specific Cases of DDD in the United States
10.4.5
Total Treated Cases of DDD in the United States
10.5
EU4 and the UK
10.6
Japan
11
Patient Journey
11.1
Description
12
Emerging Degenerative Disc Disease Therapies
12.1
Emerging Competitive Landscape
12.2
SB-01: Spine Biopharma
12.2.1
Product Description
12.2.2
Other Developmental Activities
12.2.3
Clinical Development
12.2.3.1
Clinical Trial Information
12.2.4
Safety and Efficacy
12.2.5
Analyst Views
12.3
IDCT (Rebonuputemcel): DiscGenics
12.4
Rexlemestrocel-L (MPC-06-ID): Mesoblast and Grünenthal
Note: List to be continued in the report
13
DDD Market: 7MM Analysis
13.1
Key Findings
13.2
Degenerative Disc Disease Market Outlook
13.3
Conjoint Analysis
13.4
Key Market Forecast Assumptions
13.5
Total Market Size of DDD in the 7MM
13.6
The United States Degenerative Disc Disease Market
13.6.1
Total Market Size of DDD in the United States
13.6.2
Market Size of DDD by Therapies in the United States
13.7
EU4 and the UK Degenerative Disc Disease Market
13.8
Japan Degenerative Disc Disease Market
14
Unmet Needs
15
SWOT Analysis
16
KOL Views
17
Degenerative Disc Disease Market Access and Reimbursement
17.1
The United States
17.2
In EU4 and the UK
17.3
Japan
17.4
Summary and Comparison of Market Access and Pricing Policy Developments in 2025
17.5
Market Access and Reimbursement in DDD
18
Bibliography
19
Degenerative Disc Disease Market Report Methodology
Related Reports
Degenerative Disc Disease Clinical Trial Analysis
Degenerative Disc Disease Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key DDD companies, including Spine BioPharma, Inc., Angitia Biopharmaceuticals, Mesoblast, Ltd., BioRestorative Therapies, DiscGenics, Inc., and others.
Lumbar Degenerative Disc Disease Market
Lumbar Degenerative Disc Disease Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key lumbar degenerative disc disease companies, including Spine BioPharma Inc, MCRA, Synthes USA HQ Inc, NuVasive, Globus Medical Inc, Spineology Inc, Ranier Technology Limited, DiscGenic Inc, Invibio Ltd, Yuhan Corporation, Orthofix Inc, Janssen Korea Ltd, Eisai, Globus Medical Inc, Apatech Inc., Orthofix Inc, Bone Therapeutics S.A., and others.
Chronic Lower Back Pain Market
Chronic Lower Back Pain Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CLBP companies including Mesoblast, Eli Lilly and Company, Persica Pharmaceuticals, CHABiotech, Allodynic Therapeutics, Stayble Therapeutics, Xgene Pharmaceutical, Imbrium Therapeutics, Camurus, and others.
Chronic Lower Back Pain Clinical Trial Analysis
Chronic Lower Back Pain Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key CLBP companies, including Mesoblast, Eli Lilly and Company, Persica Pharmaceuticals, CHABiotech, Allodynic Therapeutics, Stayble Therapeutics, Xgene Pharmaceutical, Imbrium Therapeutics, Camurus, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
[email protected]
+14699457679
www.delveinsight.com
SOURCE DelveInsight Business Research, LLP